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Open access under CC BThere is a need for new safe, effective and short-course treatments for leishmaniasis; one strategy is to
use combination chemotherapy. Polymer–drug conjugates have shown promise for the delivery of
anti-leishmanial agents such as amphotericin B. In this paper, we report on the preparation and biological
evaluation of polymer–drug conjugates of N-(2-hydroxypropyl)methacrylamide (HPMA), amphotericin B
and alendronic acid. The combinatorial polymer–drug conjugates were effective anti-leishmanial agents
in vitro and in vivo, but offered no advantage over the single poly(HPMA)–amphotericin B conjugates.
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Parasites of the genus Leishmania give rise to a number of differ-
ent clinicalmanifestations. Themost severe is visceral leishmaniasis
(VL),which is almost always fatal unless treated. Estimatednumbers
of new VL cases are 500,000 per annum, with approximately 50,000
deaths each year, although VL is often not recognised or reported.1
Other forms of the disease, cutaneous leishmaniasis (CL),mucocuta-
neous leishmaniasis (MCL) andpost-kala-azar dermal leishmaniasis
(PKDL) are also major problems in many parts of the world.
Drugs remain the most important tool for both treatment and
control of disease. Current drugs against VL include pentavalent
antimonials (sodium stibogluconate (Pentostam) and meglumine
antimoniate), the polyene antibiotic amphotericin B (amphotericin
B deoxycholate, Fungizone) and its liposomal formulation
(AmBisome). Recent advances in anti-leishmanial chemotherapy
include the approval of the ﬁrst oral drug miltefosine (Impavido)
and the re-discoveryof paromomycin (aminosidine).2 Paromomycin
is the latest drug to be registered for use in India against VL.
Limitations of current drugs include signiﬁcant toxicity, high cost
and long treatment courses. Drug resistance to some anti-leish-
manial drugs has developed in certain parts of the world with
one important focus in the state of Bihar in India.3x: +44 1382 386 373.
ert).
Y license.The advent of new drugs has led to a renewed interest in anti-
leishmanial combination chemotherapy as a real possibility.4 This
strategy is practiced in the treatment of TB, HIV infections and ma-
laria. Potential advantages of a combination chemotherapy ap-
proach against VL include decreased toxicity as a result of lower
drug doses and/or shorter treatment courses, better patient com-
pliance, lower cost and possibly a reduced likelihood of resistance
development.4,5
One of the issues in developing drugs against leishmaniasis is
delivery of compounds to the parasite which is found within a par-
asitophorous vacuole (PV) within macrophages. A possible solution
is to use polymer–drug conjugates to deliver compounds to the par-
asite. Polymer conjugates for lysosomotropic delivery are taken into
cells by endocytosis and then trafﬁcked through endosomes to lyso-
somes.6 The PV has many similarities to late endosomes/lysosomes
and multiple vacuole trafﬁcking pathways can intersect with Leish-
mania PV;7 therefore it is likely that the polymer–drug conjugates
can also be trafﬁcked to this compartment. Polymer–drug conju-
gates have been extensively investigated as potential therapeutics
(nanomedicines) in the anti-cancer ﬁeld.8 There are a number of dif-
ferent polymers available including synthetic and natural polymers
and biodegradable and non-biodegradable polymers. N-(2-
Hydroxypropyl)methacrylamide (HPMA) copolymer has previously
shown promise in the delivery of an anti-leishmanial 8-aminoquin-
oline.9,10 We have recently reported the anti-leishmanial activity of
poly(HPMA)–amphotericin B conjugates both in vitro and in vivo.11
In a new development, Vicent et al. have reported the design of
polymer–drug conjugates for combination therapy in cancer.12
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AmB with another drug attached to the polymer that has anti-
leishmanial activity. Requirements for attachment to the polymer
include a compound with an amine for linking to the polymer.
We decided to investigate bisphosphonates. Bisphosphonates have
been shown to have anti-leishmanial activity.13 Furthermore, some
bisphosphonates are registered for the treatment of osteoporosis,
indicating their potential pharmaceutical acceptability. We se-
lected alendronate, as this has a suitable amine function for attach-
ment to the polymer. Alendronate is a potential candidate for
delivery as a polymer conjugate as it has poor oral bioavailability,14
and poor membrane permeability, both of which could potentially
be overcome by this strategy. Here, we report on the synthesis and
biological evaluation of the ﬁrst examples of combinatorial poly(-
HPMA)–drug conjugates as potential therapeutics for VL.
2. Results
2.1. Synthesis, characterisation andpuriﬁcationof poly(HPMA)–
GFLG–AleA and poly(HPMA)–GFLG–AleA–AmB
A library of poly(HPMA)–GFLG copolymer conjugates was pre-
pared containing alendronic acid (AleA) with or without amphoter-
icin B (AmB) (Table 1). The starting point was commercially
available HPMA copolymer containing 9.03 mol % of GlyPheLeuGly
(GFLG) side chains, ending with para-nitrophenol via ester bond.
GlyPheLeuGly was chosen as a linker from the polymer to the drug,
as it is known to be cleaved by cathepsin B that is found in the PV;
hence compounds should be released in the PV. Copolymer conju-
gates containing AleA were prepared by displacement of the para-
nitrophenol by the amino function of AleA in the presence of DBU
(Fig. 1). Normally we use DMSO as solvent and triethylamine as
base for this coupling. However in this case, the alendronic acid
was insoluble in DMSO/triethylamine, but soluble in DMSO/DBU.
Unreacted GFLG-p-ONp groups were then quenched using 1-ami-
no-2-propanol (AP), to prevent cross-coupling, further reactions
and to give a well-deﬁned product. Copolymer conjugates contain-
ing AleA and AmB were synthesised in three steps. Firstly, AmB
was introduced by reaction of the GFLG-p-ONp derivative polymer
with the amino group of the drug. Next, the AleA was introduced.
Finally, unreacted GFLG-p-ONP groups were removed by reaction
with 1-amino-2-propanol (Fig. 1). Qualitative and quantitative
determination of alendronic acid were performed, respectively,
by 31P NMR and elemental analysis. The chemical shift in the 31P
NMR was typical for alendronate.15
2.2. In vitro efﬁcacy of poly(HPMA)–GFLG–AmB–AleA and
corresponding single-drug conjugates against intracellular
Leishmania donovani in peritoneal mouse macrophages (PEM)
Poly(HPMA)–GFLG–AmB–AleA conjugates were tested for their
anti-leishmanial activity against the intracellular amastigote stageTable 1
Polymers prepared and evaluated
Conjugate Total A
1 Poly(HPMA)–GFLG–ONp
3 CIR1790 Poly(HPMA)–GFLG–AleA 7.9
4 CIR1791 Poly(HPMA)–GFLG–AmB–AleA 5.5
5 CIR1792 Poly(HPMA)–GFLG–AmB–AleA 3.9
6 CIR1793 Poly(HPMA)–GFLG–AmB–AleA 1.8
7 CIR1668 Poly(HPMA)–GFLG–AmB —
8 CIR1783 Poly(HPMA)–GFLG–AmB —
9 CIR1465 Poly(HPMA)–GFLG–COOH —
10 CIR1466 Poly(HPMA)–GFLG–AP —
CIR1465, CIR1466 and CIR1668 have been reported previously.11in macrophages. Experiments aimed to compare their activity to
corresponding single-drug conjugates. For this purpose poly(-
HPMA)–GFLG–AmB and combinatorial drug conjugates carrying
similar weight percentages of amphotericin B were compared. Un-
bound amphotericin B was included for comparison and Fungi-
zone used to validate the experiment. Copolymers without
drugs attached were also evaluated for control purposes.
In agreement with our previous report11 the poly(HPMA)–
GFLG–AmB conjugates gave high anti-leishmanial activity, with
EC50 values below 1 lg/ml and of the same order of magnitude
as free amphotericin B and Fungizone (Table 2, Fig. 2). Thus
CIR1668 (9.6% amphotericin B) and CIR1783 (16.9% amphotericin
B) showed potent activity. However on its own, poly(HPMA)–
GFLG–AleA (CIR1790, 7.9% alendronic acid) showed no signiﬁcant
anti-leishmanial activity. Comparison of CIR1791 (5.5% AleA and
8.2% AmB) with CIR1668 (0% AleA and 9.6% AmB) showed the ef-
fect of adding alendronic acid to approximately 8–9% amphotericin
B loading; essentially the copolymers were equally active. A similar
effect can be seen by comparing CIR1792 (3.9% AleA and 13.4%
AmB) and CIR1793 (1.8% AleA and 19.6% AmB) with CIR1783 (0%
AleA and 16.9% AmB). These copolymers have relatively high levels
of amphotericin B (13–17%) and varying levels of alendronic acid,
but showed similar levels of anti-leishmanial activity. Finally com-
paring CIR1790 (7.9% AleA and 0% AmB) with CIR1791 (5.5% AleA
and 8.2% AmB) showed the additive effect of amphotericin B to a
loading of 5.5–7.9% alendronic acid; the copolymers went from
essentially inactive to a very good level of anti-leishmanial activity.
Hence, no advantage of the combinatorial poly(HPMA)–GFLG–
AmB–AleA conjugates was observed as compared to single-drug
poly(HPMA)–GFLG–AmB conjugates. Furthermore, there was no
signiﬁcant activity for the poly(HPMA)–GFLG–AleA conjugate
within the concentration range tested (Fig. 2).
2.3. In vivo efﬁcacy of poly(HPMA)–GFLG–AmB–AleA and
poly(HPMA)–GFLG–AmB conjugates against L. donovani in the
BALB/c mouse model
The in vivo activity of poly(HPMA)–GFLG–AmB–AleA conju-
gates was evaluated in the BALB/c mouse model at a single dose le-
vel of conjugate at 1 mg/kg amphotericin B equivalent  3 and
compared to single-drug conjugates that had shown in vitro activ-
ity. The experiment was validated with AmBisome.
Again we observed high anti-leishmanial activity of both single-
drug and combinatorial conjugates, but no advantage of adding
alendronic acid was seen (Table 3). In vivo activity of drug conju-
gates with similar amphotericin B loadings was in the same range
for single-drug and combinatorial drug conjugates. CIR1668
(9.6 wt % amphotericin B) and CIR1791 (8.2 wt % amphotericin B,
5.5 wt % alendronic acid) inhibited hepatic parasite burden by
36% and 44%. CIR1783 (16.9 wt % amphotericin B) was the most ac-
tive conjugate with an inhibition of 77.5%. In comparison CIR1792
(13.4 wt % amphotericin B, 3.9 wt % AleA) and CIR 1793 (19.6 wt %leA (% w/w) Total AmB (% w/w) Free AmB (% total drug)
— —
8.2 <1.0
13.4 <1.0
19.6 <1.0
9.6 <0.1
16.9 <0.1
— —
— —
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Figure 1. Schematic representation of the synthesis of poly(HPMA)–GFLG–AleA and poly(HPMA)–GFLG–AmB–AleA. The copolymer conjugates were prepared by amidation
reaction between the amino group of AleA and/or AmB with the p-nitrophenol ester group of the tetrapeptide GFLG side chain of copolymer precursor 1, and by a ﬁnal
quenching with 1-amino-2-propanol.
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68%. AmBisome remained the most active formulation and gave
an inhibition of 99.5% of hepatic burden. No overt signs of toxicity
were recorded in any of the treatment groups and the percentage
weight change in treated groups was <1%.
3. Discussion
Combination chemotherapy is becoming an attractive strategy
for tackling leishmaniasis. In earlier studies combinations of so-
dium stibogluconate with paromomycin were found to be safe
and effective in early trials conducted in India and East Africa.16–
18 A combination regime of sodium stibogluconate and paromomy-
cin has been employed in Sudan by MSF.19 A recent trial of 2-drugchemotherapy, single dose AmBisome followed by a short course
of miltefosine, has shown promising results for this sequential tan-
dem approach against Indian VL.4 Additionally various short course
multidrug regimes are expected to form part of the visceral leish-
maniasis elimination programme.20
A single formulation of a ﬁxed dose of two drugs has been de-
scribed as part of an ideal proﬁle for anti-malarial drug combina-
tions21 and recently a hybrid compound derived from meﬂoquine
and artesunate has been reported to be more active than a combi-
nation of both single drugs against the malaria parasite.22 How-
ever, in the case of leishmaniasis, the routes of administration
are different for most of the currently approved drugs (po for mil-
tefosine, iv for Fungizone and AmBisome, im for sodium stibo-
gluconate and im for paromomycin2) and pentavalent antimony
Table 2
EC50 and EC90 values of single and combinatorial poly(HPMA)–GFLG-conjugates against L. donovani amastigotes in peritoneal exudate macrophages, for one representative
experiment
Conjugate AmB (wt %) Al. acid (wt %) EC50 (lg/ml) EC90 (lg/ml)
Amphotericin B >95 N/A 0.06 (0.04–0.09) 0.44 (0.20–0.68)
Fungizone N/A N/A 0.07 (0.04–0.10) 0.13 (0.11–0.15)
CIR1668 9.63 0 0.09 (0.08–0.10) 0.68 (0.30–1.06)
CIR1790 0 7.88 n.o. n.o.
CIR1791 8.15 5.49 0.18 (0.09–0.27) 1.18 (0.60–1.76)
CIR1792 13.43 3.92 0.13 (0.09–0.17) 0.36 (0.20–0.52)
CIR1793 19.55 1.83 0.05 (0.03–0.07) 0.22 (0.13–0.31)
CIR1783 16.93 0 0.06 (0.04–0.08) 0.21 (0.14–0.28)
CIR1465 0 0 n.o. n.o.
CIR1466 0 0 n.o. n.o.
The infection level in untreated controls was 77%. Values are given as amphotericin B equivalent in lg/ml with 95% conﬁdence intervals in brackets (n = 4). Drug loading is
given in weight% (wt %). N/A not applicable, n.o. not obtained as CIR1465,11 CIR146611 and CIR1790 were inactive within the concentration range tested. No toxicity to the
macrophages was observed at the concentrations of copolymer used.
Figure 2. Exposure–response curves for poly(HPMA)–GFLG–AmB, poly(HPMA)–GFLG–AleA and poly(HPMA)–GLFG–AmB–AleA conjugates. (A) compares CIR1668 (9.6 wt %
AmB) and CIR1791 (8.2 wt % AmB, 5.5 wt % AleA). (B) compares CIR1783 (16.9 wt % AmB), CIR1792 (13.4 wt % AmB, 3.9 wt % AleA) and CIR1793 (19.6 wt % AmB, 1.8 wt %
AleA). CIR1790 contains 7.9 wt % AleA. AmB refers to the free drug tested (77% infected macrophages in control). Corresponding alendronic acid (AleA) equivalents at 1 lg/ml
amphotericin B equivalent are as follows: 0.675 lg/ml for CIR1791, 0.290 lg/ml for CIR1792 and 0.092 lg/ml for CIR1793. CIR1790 was used at a starting concentration of
0.675 lg/ml, corresponding to the highest concentration in the combinatorial conjugates (92% infected macrophages in control). Data points give the arithmetic mean ± SEM
(n = 4) for one representative experiment. Drug equivalent for combination polymers refers to amphotericin B.
Table 3
Inhibition of hepatic parasite burden after treatment with CIR1668, CIR1783, CIR1791, CIR1792 and CIR1793
Code name Conjugate AmB loading Ale acid loading % Inhibition ± SEM LDU ± SEM
CIR1668 Poly(HPMA)–GFLG–AmB 9.6 wt % 0 36.1 ± 10.4 1672 ± 139
CIR1783 Poly(HPMA)–GFLG–AmB 16.9 wt % 0 77.5 ± 3.0 1672 ± 139
CIR1791 Poly(HPMA)–GFLG–AmB–Ale acid 8.2 wt % 5.5 wt % 44.4 ± 2.6 1672 ± 139
CIR1792 Poly(HPMA)–GFLG–AmB–Ale acid 13.4 wt % 3.9 wt % 53.8 ± 5.2 1672 ± 139
CIR1793 Poly(HPMA)–GFLG–AmB–Ale acid 19.6 wt % 1.8 wt % 67.9 ± 6.9 1672 ± 139
AmBisome n/a n/a n/a 99.5 ± 0.2 1672 ± 139
Values presented give the arithmetic mean ± SEM of treated groups (n = 5).
LDU Leishman–Donovan unit at the experimental endpoint.
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due to high resistance levels.23 This means ﬁxed-dose combination
regimes with ease of administration and using a single route of
administration, are problematic in most Leishmania endemic re-
gions, including the region carrying most of the VL burden. There-
fore, a delivery system that would guarantee concurrent
administration of two or more drugs coupled with the advantage
of timely equal delivery at the site of infection, notably Leishmania
containing macrophages and at a subcellular level the parasitoph-
orous vacuole, does appear attractive.
In this paper, we describe the use of water-soluble polymer–
2-drug conjugates for simultaneous delivery of multiple agents.This approach has been successfully undertaken experimentally
in the anti-cancer ﬁeld,12 where Vicent et al. simultaneously
delivered a cytotoxic agent (doxorubicin) and endocrine therapy
(aminoglutethimide). In their study, the drugs showed a syner-
gistic effect when combined on the same polymer, which was
not evident when mixtures of polymer conjugates with each
agent individually on the polymer backbone were used. Interest-
ingly, the combination appeared to have different release kinet-
ics compared to the individual agents when coupled separately
to polymer.
We attached amphotericin B and alendronic acid to the HPMA
backbone, obtaining soluble conjugates. The polyene antibiotic
S. Nicoletti et al. / Bioorg. Med. Chem. 18 (2010) 2559–2565 2563amphotericin B complexes with 24-substituted sterols, such as
ergosterol in cell membranes, causing channel formation which al-
ters ion balance and results in cell death.24 Alendronic acid is a
nitrogen-containing bisphosphonate (NBp). NBps have been dem-
onstrated to inhibit isoprenoid biosynthesis at the farnesyl pyro-
phosphate synthase (FPPS) level of the mevalonate pathway.25
NBps, notably alendronate, pamidronate and risedronate, have
shown in vitro activity of varying order of magnitude against intra-
cellular L. donovani amastigotes and other parasitic protozoa.13 In
this case, alendronate was reported to have an EC50 of 83 lM
against intracellular amastigotes. In vivo activity has been demon-
strated for pamidronate against experimental CL caused by L. ama-
zonensis,26 as well as for pamidronate and risedronate against L.
donovani in the BALB/c mouse model.27 NBps are charged mole-
cules with poor oral bioavailability,14,28 and once in the body, bis-
phosphonates are taken up by the skeleton.29 Attachment of these
compounds to a polymer backbone might result in more favour-
able cell targeting for Leishmania, although a report has indicated
that polymer bound alendronate may still be targeted to the
bone.30 Unfortunately, no activity was seen with the poly(-
HPMA)–GFLG–AleA copolymer in vitro. It may be that the alend-
ronic acid is not released from the polymer, or that it is not
delivered to infected macrophages in sufﬁcient concentration to
have an effect.
Although we were able to conﬁrm our previous report of high
anti-leishmanial in vitro and in vivo activity of poly(HPMA)–
GFLG–AmB conjugates, combinatorial poly(HPMA)–GFLG–AmB–
AleA conjugates did not show advantage over the single drug
poly(HPMA)–GFLG–AmB polymer conjugates. The failure to ob-
serve any increase in drug activity by administration of the
two pendant drugs could be due to the nature of alendronic acid
and its low potency against Leishmania. Indeed free bisphospho-
nates do not show high intrinsic anti-leishmanial activity apart
from risedronate. However the use of risedronate was not possi-
ble in this study due to chemistry constraints. Alendronic acid
appeared to have a low therapeutic index in vitro with variabil-
ity between experiments (personal observation) and the alend-
ronic acid containing conjugate without amphotericin B did not
show inherent anti-leishmanial activity. Low potency of pendant
drugs is an acknowledged factor in the failure of drug delivery
systems.8 Additionally we do not know at present if drug release
from the polymer backbone is necessary for activity, neither how
and if amphotericin B and alendronic acid are released. Further
experiments would reveal if the drugs are released in the envi-
ronment of the parasitophorous vacuole. Incubation with cathep-
sin B6,31 or tritosomes to look for drug release32 have been
reported for investigating drug release from polymer–drug
conjugates.
It still has to be noted that single-drug and combinatorial drug
conjugates retained high anti-leishmanial activity and the present
alendronic acid loading did not appear to have a negative effect on
anti-leishmanial drug activity. No apparent signs of toxicity were
recorded for either single drug or combinatorial drug conjugates.
4. Conclusions
As far as we are aware, this is the ﬁrst report on anti-leishman-
ial drug combinations based on a macromolecular drug delivery
system for anti-leishmanial chemotherapy. Further investigations
into copolymers carrying two pendant drugs as a novel approach
for anti-leishmanial combination chemotherapy will be useful. By
choosing drugs with a higher inherent anti-leishmanial activity
an effective combinatorial drug delivery systemmight be obtained.
The high efﬁcacy of poly(HPMA)–GFLG–AmB conjugates was
conﬁrmed.5. Experimental
5.1. Materials, instruments and methods
HPMA copolymer with a weight average molecular weight
(Mw) of 37,427 g/mol and a polydispersity (Mw/Mw) of 1.58, con-
taining 9.03 mol % GlyPheLeuGly linker activated as the para-nitro-
phenol ester (ONp) (poly(HPMA)–GFLG–ONp) was purchased from
Polymer Laboratories Ltd, Church Stretton, UK. Triethylamine was
distilled from potassium hydroxide and stored under nitrogen.
Amphotericin B with a content of amphotericin A less than 5%
was purchased from A.G. Scientiﬁc, Inc. San Diego CA. Alendronic
acid was purchased from AK Scientiﬁc, Inc. Mountain View CA.
Other reagents and solvents were purchased from Aldrich and Flu-
ka. All the reactions were carried out at room temperature under
argon atmosphere unless speciﬁed.
Normal phase thin layer chromatography (TLC) was performed
using pre-coated sheets of Silica 60F254, using methanol as mobile
phase (Rf of amphotericin B = 0.31; Rf of 4-nitrophenol and of the
polymer = 0.9). Sephadex™ LH20 and dialysis membrane (Molecu-
lar Weight Cut Off of 2000, regenerated cellulose tubing Spectra/
Por 6) were purchased from Fisher Scientiﬁc.
1H NMR spectra were recorded on a Bruker Avance DPX 500
spectrometer. All the signals are described as broad (br). UV–vis
spectra were recorded on a Beckman DU 640 spectrophotometer.
Solid phase extraction (SPE) high performance liquid chromatogra-
phy (HPLC) analyses were performed using a Dionex Ultimate
3000 HPLC instrument, using a lBondapack C18 10 lm 125 Å,
300 mm  4.6 mm I.D. column (Waters). SPE was carried out using
Bond Elut C18 cartridges of 3 ml capacity containing 100 mg of
stationary phase (Varian). Microwave experiments were per-
formed in a Biotage Initiator Reactor (Biotage, UK). Elemental anal-
yses were performed by MEDAC Ltd (UK).
5.2. Synthesis of polymer–drug conjugates
Syntheses of poly(HPMA)–GFLG–AmB (CIR1668) has been re-
ported recently and that of HMPA–GFLG–AmB (CIR1783) was car-
ried out using our previously reported methodology.11
5.3. Synthesis of poly(HPMA)–GFLG–alendronic acid conjugate
(CIR1790)
To a stirred solution of poly(HPMA)–GFLG–ONp (9.03 mol %)
(424.2 mg, 0.22 mmol ONp) in dry DMSO (10.0 ml) was added
896 ll (0.031 mmol) of a solution of alendronic acid (107.0 mg,
0.43 mmol, dissolved in 12.0 ml of DMSO and 323.0 ll of DBU,
2.16 mmol, heated in the microwave reactor at 200 C for 10 s).
The resulting mixture was stirred overnight, quenched with 90 ll
of 1-amino-2-propanol (1.17 mmol), diluted with water, after-
wards it was dialysed and freeze dried. White foam, 310 mg. Yield
based on polymer weight, 73.1%. 1H NMR (500 MHz, CD3OD); d
1.02–4.53 [br, H of HPMA, glycine, leucine, phenylalanine and 1-
amino-2-propanol, and alendronic acid]; d 7.15 and 7.4 [br, Ph, of
phenylalanine]. 31P NMR (121 MHz, CD3OD); d 19.8 [P of PO3H2
in alendronate)].
5.4. Synthesis of poly(HPMA)–GFLG–alendronic acid–AmB
conjugates (example described for CIR 1792)
A solution of amphotericin B (72.79 mg dissolved in 1.7 ml of
dry DMSO, 0.076 mmol) and triethylamine (11.0 ll, 0.078 mmol)
were added to a stirred solution of poly(HPMA)–GFLG–ONp
(9.03 mol % ONp) (302.45 mg, 0.15 mmol ONp) in dry DMSO
(3.0 ml) with monitoring by normal phase TLC. After two hours
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solution was stirred for one hour more and a solution of alendronic
acid was added to it (20.07 mg, 0.078 mmol, dissolved in 2.0 ml of
DMSO and 60 ll of DBU, 0.39 mmol, heated in the microwave reac-
tor at 200 C for 10 s). The resulting solution was stirred for 16 h
and quenched with 1-amino-2-propanol (60 ll, 0.78 mmol). The
obtained reaction mixture was poured in diethyl ether, the suspen-
sion was centrifuged and the supernatant was removed. The pellet
(a brown rubbery polymer) was dissolved in a minimum amount of
methanol and puriﬁed by gel ﬁltration using LH20 as stationary
phase and methanol as eluent. All the fractions were monitored
by UV–vis at 407 nm. The fractions related to the ﬁrst peak (poly-
mer conjugate) were collected, the solvent was removed and the
yellow residue was dissolved in water and freeze dried. The prod-
uct was a yellow foam 210.0 mg (yield based on polymer weight,
69.5%); 1H NMR (500 MHz, CD3OD); d 1.01–5.92 [br, H of HPMA,
glycine, leucine, phenylalanine, amphotericin B and alendronic
acid]; d 6.39 [br, H of double bonds in amphotericin B]; d 7.39
and 7.58 [br, H of Ph in phenylalanine]. 31P NMR (121 MHz,
CD3OD); d 19.7 [P of PO3H2 in alendronate)].
CIR1791 and CIR1793 were made using the same protocol, but
with different quantities of reagents.
5.5. Analytical methods
The total amphotericin B content in polymer–drug conjugates
was determined using UV–vis spectroscopy and the levels of free
unbound, residual amphotericin B in polymer–drug conjugates
by SPE-HPLC as previously reported.11 The total levels of alendron-
ic acid in polymer–drug conjugates was determined by elemental
analysis of phosphorus levels.
5.6. In vitro anti-leishmanial activity testing
L. donovani strain MHOM/ET/67/L82 was maintained in Syrian
hamsters (Mesocricetus auratus) and amastigotes harvested from
the spleen of an infected animal.
Peritoneal exudate macrophages (PEMs) were harvested from
CD1 mice (Charles River Ltd, Margate, UK) by lavage with cold
RPMI 1640 medium (Sigma) 24 h after injecting 2 ml of 2% soluble
starch (Sigma) into the peritoneal cavity. Macrophages were plated
in Lab-tek 16-well chamber slides (Nunc, USA) at a density of
5  104 cells/well and left to adhere O/N at 37 C in a 5% CO2–
95% humidiﬁed air mixture. Adherent PEMs were infected with L.
donovani amastigotes at a ratio of ﬁve amastigotes to one macro-
phage. After O/N incubation at 37 C in 5% CO2 in humidiﬁed air
non-phagocytosed amastigotes were removed and 200 ll of three-
fold serially diluted drug and polymer solutions added to the
respective wells. Stock solutions of free amphotericin B, poly(-
HPMA)–GFLG–AmB conjugates and poly(HPMA)–GFLG–AmB–AleA
conjugates were prepared in 100% DMSO (dimethyl sulfoxide, Sig-
ma) at 1 mg/ml amphotericin B equivalent. Fungizone was recon-
stituted according to manufacturer’s protocol to obtain a 5 mg/ml
stock of amphotericin B. All subsequent dilutions were prepared
in RPMI 1640 medium plus 10% hi-FCS. Six concentrations were
tested, ranging from 1 to 0.004 lg/ml amphotericin B equivalent.
Each drug concentration was tested in quadruplicate. Maximum
DMSO concentration in the assays was 0.1%, which had no effect
on macrophage parasite clearance.
Infected cultures were incubated for 72 h at 37 C in a 5% CO2–
95% humidiﬁed air mixture. At experimental endpoint slides were
ﬁxed with 100% methanol and stained with 10% Giemsa in water.
Percentage inhibitions caused by drug and conjugate activity were
determined from the percentage of infected macrophages in rela-
tion to a non-treated control upon microscopically counting of
100 macrophages per well. Data were ﬁtted using the non-linearsigmoidal curve-ﬁtting Levenburg Marquardt algorithm and EC50/
EC90 values estimated using Microsoft xlﬁt (ID Business Solution,
Guildford, UK). Two independent experiments were performed.
5.7. In vivo anti-leishmanial activity testing
All animal experiments were conducted under licence in accor-
dance with UK Home Ofﬁce regulations. Female Balb/c mice were
infected by injection of 2  107 amastigotes in 0.2 ml RPMI med-
ium without serum into the tail vein and randomly sorted into
groups of ﬁve. Solutions of poly(HPMA)–drug conjugates were pre-
pared in PBS (phosphate buffered saline, Sigma). AmBisome (Gi-
lead Scienes) was reconstituted according to manufacturer’s
protocol to yield a stock solution of 4 mg/ml amphotericin B. Sub-
sequent dilutions of AmBisome were prepared in 5% dextrose.
Groups of ﬁve mice were dosed intravenously (iv) at an amphoter-
icin B equivalent of 1 mg/kg on days 7, 9 and 11 post-infection with
a bolus injection of 0.2 ml using 25 gauge needles. AmBisomewas
included at the same dose of 1 mg/kg amphotericin B equivalent.
On day 14 post-infection mice were killed and impression smears
of livers taken after weighing the organs. Group weights were re-
corded before and after treatment. Smears were ﬁxed in 100%
methanol, stained in 10% Giemsa in water and the number of
amastigotes per 500 host cell nuclei counted. The number of Leish-
man–Donovan units (LDU) was calculated using the formula:
LDU = number of parasites per host cell nucleus  organ weight
in mg.33 Deviations from the number of host cell nuclei given
above were taken into account and corrected for by changing the
reference base.
Reduction in parasite burden achieved in a particular animal
was calculated relative to the mean LDU (n = 5) of the control
group and expressed as percentage inhibition.
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